| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | Cemiplimab Basic information |
| Product Name: | Cemiplimab | | Synonyms: | Cemiplimab;Research Grade Cemiplimab(DHH02201);Cemiplimab (anti-PD-1);REGN-2810|||SAR-439684;Research Grade Cemiplimab;Immunoglobulin G4, anti-(human programmed cell death protein 1) (human monoclonal REGN2810 heavy chain), disulfide with human monoclonal REGN2810 κ-chain, dimer (ACI) | | CAS: | 1801342-60-8 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Cemiplimab Structure]() |
| | Cemiplimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Cemiplimab Usage And Synthesis |
| Uses | Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research[1][2]. | | in vivo | Cemiplimab (i.p., 10 mg/kg, five injections within 2 weeks) can increased the proportion of effector T cells in tumors and dLNs to reduce tumor growth by combined immunotherapy with REGN3767 in MC38.Ova tumor mice model[2].
| Animal Model: | Female human PD-1×LAG-3 knockin mice (8-10 weeks) with MC38.Ova cells[2] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; five injections within 2 weeks | | Result: | Partially inhibited the growth of MC38.Ova tumors and prolonged the survival of mice by administering alone.
Significantly increased the proportion of CD4+ TILs in IFNγ and TNFα by combined immunotherapy with REGN3767.
|
| | References | [1] Michael R Migden, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351. DOI:10.1056/NEJMoa1805131
[2] Elena Burova, et al. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther. 2019 Nov;18(11):2051-2062. DOI:10.1158/1535-7163.MCT-18-1376 |
| | Cemiplimab Preparation Products And Raw materials |
|